Note the date on that -- January, 2015, a year and a half ago. The FDA has been saying that they're trying to expedite drug approvals, and something as potentially beneficial as Kevetrin would certainly qualify for expedited approval if shown to be as effective as the Phase 1 data indicates it might be. There was an MS drug that was expedited just in the last week or so. A cancer drug would affect FAR more people than an MS drug. (Happy as I am that there is finally something for the non-relapsing/remitting form of MS, which has been essentially untreatable until now, nevertheless it doesn't affect nearly as many people -- although I do know someone with this terrible form of MS and it's great that she now has a chance at treatment.)